In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Mircera 12.5μg Version Approved in Japan: Chugai
March 22, 2018
- Life Science Institute to Launch Cell Processing Center for Muse Cells, Aiming to Commence Operations in Jan. 2019
March 22, 2018
- Toho Forms Capital Alliance with Tokyo Upstart HekaBio
March 20, 2018
- Hitachi Chemical Wins Clinical Regenerative Medicine Manufacturing Deal from Daiichi Sankyo
March 20, 2018
- Opdivo Picks Up HCC Nod in Taiwan
March 20, 2018
- Top Court Slaps Down Debiopharm’s Appeal over Elplat Patent
March 20, 2018
- Xtandi Gets FDA Priority Review Status for Add’l CRPC Indication
March 20, 2018
- IBL, Astellas Wind Up Human Fibrinogen Collaboration
March 20, 2018
- Bioverativ Earns Approval for 4,000 IU Version for Hemophilia B Treatment Alprolix
March 20, 2018
- Toho to Thoroughly Implement Drug Distribution GL, Focus on Cost-Cutting in Response to Impact of Drug Pricing Reform: Pres.
March 20, 2018
- Takeda Bolstering Pitch for Inisync, Takecab in December: Anterio Ranking
March 19, 2018
- Ethical Drug Sales Up 3.6% in January on AbbVie Hep C Drug, Seasonal Factors
March 19, 2018
- EMA Accepts Filing for Xtandi’s CRPC Label Expansion
March 19, 2018
- Shionogi Nabs Rights to Osaka Upstart’s Tissue Regeneration-Inducing Peptide
March 16, 2018
- Japan Likely the Only Negative Growth Pharma Market in 2018-2022: IQVIA
March 16, 2018
- Rohto Wins Japan Exclusive Rights to JT’s JAK Inhibitor in Ophthalmology Field
March 16, 2018
- Ono Exercises Option to Ink New Autoimmune Disease Deal with Merus
March 15, 2018
- Shionogi’s Single-Dose Flu Med Xofluza Hits Japan Shelves
March 15, 2018
- Kaketsuken, Meiji-Kumamoto JV, Ink Deal on Share Transfer of New Company, with Completion Date Set on July 2
March 15, 2018
- Re-Pricing Rule for Indication Expansions Mars I/O Development: MSD Japan Chief
March 14, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…